PMID: 9431894Feb 12, 1998Paper

Specific mediator-directed therapy for gastrointestinal diseases

European Journal of Gastroenterology & Hepatology
W A Stack, C J Hawkey

Abstract

A number of inflammatory mediators--such as proinflammatory cytokines, lipid derived eicosanoids and reactive oxygen metabolites--are elevated in chronic bowel inflammation. Existing drugs for Crohn's disease and ulcerative colitis, for example aminosalicylates and corticosteroids, work at many sites in the inflammatory cascade to control disease activity. These drugs may be associated with significant side-effects and do not always control the disease. Therefore there is an impetus to develop treatments which are safer and more specific for bowel inflammation. Specific inhibitors of inflammatory mediators have recently become available and some have been shown to be effective in animal models of bowel inflammation. Although far fewer data are currently available on specific mediator-directed therapy of intestinal inflammation in humans, early clinical trials in inflammatory bowel disease have given mixed results. It remains to be determined whether or not this strategy of specific mediator inhibition is an alternative to current therapy for chronic bowel inflammation in humans.

Citations

Jun 27, 2000·Prostaglandins & Other Lipid Mediators·B Mohajer, T Y Ma
Feb 6, 2007·International Immunopharmacology·Laura Camacho-BarqueroCatalina Alarcón de la Lastra
Feb 24, 2000·The American Journal of Gastroenterology·O H NielsenN H Heegaard
Apr 10, 1999·Hospital Medicine·S Pathmakanthan, W A Stack

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.